Gefinitib, which inhibits growth of the epidermal growth factor receptor (EGFR), showed no benefit to patients with advanced hormone-resistant breast tumors, according to a study in the Annals of Oncology. Patients included those with hormone-negative breast cancer and those with hormone-positive that had not responded to hormone therapy such as tamoxifen or an aromatase inhibitor. The latter is called hormone resistant, even though it is biologically hormone positive. Forty-five patients were given 500 mg of Gefinitib daily. Twenty-five were hormone-negative. At 24 weeks, enrollment was ceased because of low response. The conclusion: For these patients, tumors were not reduced and Gefinitib did not result in a clinical benefit rate (CBR).
SOURCE: Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., and Australian New Zealand Breast Cancer Trials Group (2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 20(11):1813-1817.